Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents

• Published in: Journal of the American College of Cardiology Vol. 50; no. 12; pp. 1123 - 1131
• Main Authors: Togni, Mario, MD, Eber, Stéphanie, BA, Widmer, Jeannette, BA, Billinger, Michael, MD, Wenaweser, Peter, MD, Cook, Stéphane, MD, Vogel, Rolf, MD, PhD, Seiler, Christian, MD, FACC, Eberli, Franz R., MD, Maier, Willibald, MD, Corti, Roberto, MD, Roffi, Marco, MD, Lüscher, Thomas F., MD, Garachemani, Ali, MD, Hess, Otto M., MD, FACC, Wandel, Simon, MS, Meier, Bernhard, MD, FACC, Jüni, Peter, MD, Windecker, Stephan, MD
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2007
• Subjects: Cardiovascular; Internal Medicine; major adverse cardiac events; SES; RVD; target lesion revascularization; reference vessel diameter; sirolimus-eluting stent(s); drug-eluting stent(s); percutaneous coronary intervention; DES; MACE; paclitaxel-eluting stent(s); PCI; TLR; PES
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2007.06.015

Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial Mario Togni, Stéphanie Eber, Jeannette Widmer, Michael Billinger, Peter Wenaweser, Stéphane Cook, Rolf Vogel, Christian Seiler, Franz R. Eberli, Willibald Maier, Roberto Corti, Marco Roffi, Thomas F. Lüscher, Ali Garachemani, Otto M. Hess, Simon Wandel, Bernhard Meier, Peter Jüni, Stephan Windecker Percutaneous coronary intervention (PCI) in small vessels is associated with an increased risk of restenosis and major adverse cardiac events (MACE). We performed a stratified analysis according to vessel size of angiographic and clinical outcome up to 2 years after PCI within a randomized trial (SIRTAX [Sirolimus-Eluting Stent Compared With Paclitaxel-Eluting Stent for Coronary Revascularization]) comparing sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). In patients with small-vessel stents, SES reduced MACE by 55% and target lesion revascularization by 69% compared with PES, whereas differences were less pronounced in patients with large- and with both small- and large-vessel stents. The SES appeared to be more effective than PES in reducing clinical and angiographic measures of restenosis, particularly in small vessels.